BioSpace News Archive

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on Wednesday, November 16, 2022, which includes a presentation beginning at 12:00 pm CT.

Oramed Pharmaceuticals Inc. today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (“T2D”) patients with non-alcoholic steatohepatitis (“NASH”) on Thursday, November 17, 2022, at 11:00 a.m. Eastern Standard Time.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a treatment of first line metastatic pancreatic ductal adenocarcinoma (mPDAC).

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date 2022 financial results and provided a corporate update.

Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255 on the efficacy of human CD19 CAR-T cells in a xenogeneic lymphoma model and on CD8+ T effector cell (Tcell) and natural killer (NK) cell proliferation in non-human primates.

Eikonoklastes Therapeutics, a preclinical biotech company developing a 1st-in-class, AAV9-based gene therapy for treatment of sporadic and familial amyotrophic lateral sclerosis (ALS), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the ET-101 program.

Saranas, Inc. announced today that over 1,200 patients have been treated with the Early Bird® Bleed Monitoring System, the first and only FDA-approved bleed detection system.

Therapeutic Solutions International (TSOI) announced today the launching of a spin-off company, Breathe Biologics, Inc., to commercialize technologies in the area of COPD.

Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds

The global acute repetitive seizures market size is projected to hit around US$ 18.5 billion by 2030 and register a compound annual growth rate (CAGR) of about 46.7% from 2022 to 2030.